1043 related articles for article (PubMed ID: 17194517)
21. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
22. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice.
Naik RS; Hartmann J; Kiewert C; Duysen EG; Lockridge O; Klein J
J Pharm Pharm Sci; 2009; 12(1):79-85. PubMed ID: 19470293
[TBL] [Abstract][Full Text] [Related]
23. Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system.
Zivin M; Pregelj P
Psychiatr Danub; 2008 Jun; 20(2):168-73. PubMed ID: 18587286
[TBL] [Abstract][Full Text] [Related]
24. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats.
Wang H; Tang XC
Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):27-30. PubMed ID: 10375753
[TBL] [Abstract][Full Text] [Related]
25. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
[TBL] [Abstract][Full Text] [Related]
26. The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease.
Duysen EG; Li B; Lockridge O
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):523-8. PubMed ID: 19416087
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors.
Hu Y; Zhang J; Chandrashankra O; Ip FC; Ip NY
Bioorg Med Chem; 2013 Feb; 21(3):676-83. PubMed ID: 23273608
[TBL] [Abstract][Full Text] [Related]
28. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
29. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
30. Comparison of methods used for the determination of cholinesterase activity in whole blood.
Naik RS; Doctor BP; Saxena A
Chem Biol Interact; 2008 Sep; 175(1-3):298-302. PubMed ID: 18555980
[TBL] [Abstract][Full Text] [Related]
31. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
32. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Zurek E; Szymański P; Mikiciuk-Olasik E
Drug Res (Stuttg); 2013 Mar; 63(3):137-44. PubMed ID: 23447117
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon.
Amitai G; Moorad D; Adani R; Doctor BP
Biochem Pharmacol; 1998 Aug; 56(3):293-9. PubMed ID: 9744565
[TBL] [Abstract][Full Text] [Related]
35. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
36. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
37. Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives.
Yan J; Sun L; Wu G; Yi P; Yang F; Zhou L; Zhang X; Li Z; Yang X; Luo H; Qiu M
Bioorg Med Chem; 2009 Oct; 17(19):6937-41. PubMed ID: 19726199
[TBL] [Abstract][Full Text] [Related]
38. Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase.
Li B; Duysen EG; Poluektova LY; Murrin LC; Lockridge O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):152-65. PubMed ID: 16443250
[TBL] [Abstract][Full Text] [Related]
39. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits.
Geerts H; Guillaumat PO; Grantham C; Bode W; Anciaux K; Sachak S
Brain Res; 2005 Feb; 1033(2):186-93. PubMed ID: 15694923
[TBL] [Abstract][Full Text] [Related]
40. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
Scacchi R; Gambina G; Moretto G; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):502-7. PubMed ID: 18780301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
